We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
9.50 | 0.58% | 1,645.50 | 1,645.00 | 1,645.50 | 1,656.00 | 1,635.00 | 1,642.00 | 1,852,423 | 13:42:46 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.78 | 67.89B |
Date | Subject | Author | Discuss |
---|---|---|---|
08/2/2018 13:43 | Excerpts from an article in today's Telegraph: 'NHS patients should be allowed to vape indoors and even in their beds, public health body advises Hospitals have been told to start selling e-cigarettes and letting patients vape indoors - and even in bed - under controversial new health advice. Public Health England (PHE) said every smoker struggling to quit, including pregnant women, should be encouraged to take up e-cigarettes. Officials urged hospitals to replace smoking shelters with vaping lounges, and said patients should even be allowed to vape in their beds, if they had single rooms. And they said the devices should be given out by GPs on prescription, to encourage wider takeup. The calls come as PHE published an independent review into the evidence surrounding e-cigarettes. The report, by experts from King's College London and the UK Centre for Tobacco and Alcohol Studies, the University of Stirling and Cancer Research UK, suggests e-cigarettes are helping up to 57,000 smokers a year to quit. And it restated previous claims that vaping is at least 95 per cent less harmful than smoking, while putting the increased cancer risk at less than 0.5 per cent.' That's just the opening of a looong article, but contains most of the substantive points made. | jrphoenixw2 | |
08/2/2018 13:01 | Go to your app in settings and untick notifications box! | abdullla | |
08/2/2018 12:49 | A question for this group, since it's a busy board someone might know... I follow about 5-10 different topics on various shares. Each time anyone posts in any of those topics I get an e-mail notification. It's OTT, I can get scores a day, and I'm abroad on hols in a low-tech country soon where my current daily in-box volume just wouldn't be practical/possible. Is there a way to reduce the number of notifications - other than to stop following topics completely during periods of absence? On a couple of other forums I follow if you receive e-mail notifications, you receive just one however many new messages there are. You then receive no more, until you've visited and got up to date on the topic. That is the kind of function here I'd love to find or somehow imitate. What do other people when off on holiday to reduce the volume of notifications? Thanks for any tips! | jrphoenixw2 | |
08/2/2018 12:28 | @12.23pm UK time, the volume is 7.99M. The half-way point on a day's session is 12.15pm, materially the same. Trailing 30-day full-day average volume has been 8.45M Say (8*2)/8.5 = Volume currently running at 188% of 30-day average. Px up 1.88% on the back of it. [all live data at time of writing] | jrphoenixw2 | |
08/2/2018 12:27 | hosede,Your a dreamer !!! | garycook | |
08/2/2018 12:22 | No chance. | pineapple1 | |
08/2/2018 12:14 | Regardless of GSK's results, the decline in the US has only just started - could easily drop 40% this year and It will inevitable drag everything down with it. Well done to those who made a quick profit, but I see sub 1000 on the horizon | hosede | |
08/2/2018 10:40 | PRESS RELEASE ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment TANGO study will investigate dolutegravir (TIVICAY) and lamivudine (EPIVIR) in patients with HIV who have achieved viral suppression on a tenofovir alafenamide fumarate-based regimen London, UK 8 February 2018 - Today ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the start of a phase III study designed to establish if adults with HIV-1 with current virologic suppression on a tenofovir alafenamide fumarate (TAF)-based regimen of at least three drugs are able to maintain viral suppression upon switching to a two-drug regimen (2DR) of dolutegravir (TIVICAY) and lamivudine (EPIVIR). TANGO will seek to enrol approximately 550 adults with HIV-1, from clinical trial sites in North America, Europe, Australia, and Japan. | tradermichael | |
08/2/2018 10:38 | You read my mind ...... ;0) | tradermichael | |
08/2/2018 10:36 | V shaped recovery underway | ny boy | |
08/2/2018 10:33 | Soon be 1450p p.e13 still cheap, lol. | montyhedge | |
08/2/2018 10:31 | "Abdullahs gone quiet"Just when I am counting money the share price goes up and I have to start again,can't you see I am busy,Lol ! | abdullla | |
08/2/2018 10:28 | Watching the trades this morning looks like some serious buyers coming in. | tim 3 | |
08/2/2018 10:01 | That's it 1450p a certainty, is my opinion. | montyhedge | |
08/2/2018 09:50 | Abdullahs gone quiet | badtime | |
08/2/2018 09:00 | My thoughts are a great run up to ex div 22nd Feb, for that lovely 23p dividend. Even then when ex div, I don't think they will drop 23p on that day. | montyhedge | |
08/2/2018 08:54 | Definitely in play for dip buying or adding on dips, ex div 22 Feb | ny boy | |
08/2/2018 08:52 | I bought yesterday before the results. Technically it was very oversold . Still oversold and now in a bull run . Should be more to come | juju44 | |
08/2/2018 08:35 | Yes at 1650p they looked good value last April. | montyhedge | |
08/2/2018 08:32 | No one takes any notice of them. No one can argue with free cash flow up 11%. 1450p is the right price, just under 13 p.e. Even then p.e13 good value, when Dow on average 17. | montyhedge | |
08/2/2018 08:22 | IC given another sell rec,might explain the rise lol. | tim 3 | |
08/2/2018 08:13 | I look at the free cash flow up 11% for a big company I think that is outstanding.So p.e around 11.6, yield 6.3%At 1450 pe still only 13. Is it me or as the market missed something. | montyhedge | |
08/2/2018 08:01 | £ getting weaker again, good for GSK.Even bears know the figures yesterday were superb. lol | montyhedge |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions